T2ND34 Stock Overview
A medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tandem Diabetes Care, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.74 |
| 52 Week High | US$18.90 |
| 52 Week Low | US$7.53 |
| Beta | 1.35 |
| 1 Month Change | 19.26% |
| 3 Month Change | -2.51% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| T2ND34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -0.7% | -1.2% | -1.1% |
| 1Y | n/a | 6.4% | -14.1% |
Return vs Industry: Insufficient data to determine how T2ND34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how T2ND34 performed against the BR Market.
Price Volatility
| T2ND34 volatility | |
|---|---|
| T2ND34 Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BR Market | 9.7% |
| 10% least volatile stocks in BR Market | 3.0% |
Stable Share Price: T2ND34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: T2ND34's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,400 | John Sheridan | www.tandemdiabetes.com |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Tandem Diabetes Care, Inc. Fundamentals Summary
| T2ND34 fundamental statistics | |
|---|---|
| Market cap | R$14.63b |
| Earnings (TTM) | -R$784.10m |
| Revenue (TTM) | R$5.28b |
2.8x
P/S Ratio-18.7x
P/E RatioIs T2ND34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T2ND34 income statement (TTM) | |
|---|---|
| Revenue | US$854.35m |
| Cost of Revenue | US$428.94m |
| Gross Profit | US$425.41m |
| Other Expenses | US$552.20m |
| Earnings | -US$126.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 49.79% |
| Net Profit Margin | -14.84% |
| Debt/Equity Ratio | 146.6% |
How did T2ND34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/01 12:24 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tandem Diabetes Care, Inc. is covered by 36 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | Barclays |
| Matt Miksic | Barclays |